A practical reference on desiccant: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
Temperature is the most common controlled variable, but its effect is not linear. Lower temperatures reduce most chemical reaction rates, yet freezing can concentrate solutes and create pH shifts in the remaining liquid phase. Repeated freeze-thaw cycles can denature or aggregate some peptides, especially those with hydrophobic segments. For lyophilized powders, desiccation and protection from moisture are often more important than deep freezing. For solutions, the choice between refrigeration and freezing depends on peptide concentration, buffer components, and the intended duration of storage.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or inert plastic | Compatibility depends on peptide and solvent |
| Headspace gas | Nitrogen or argon | Used to limit oxygen exposure |
| Common reconstitution solvent | Water or buffered aqueous solution | Organic co-solvents may be needed for hydrophobic peptides |
| Freeze-thaw stability | Varies by peptide | Aliquoting reduces repeated cycles |
| Documentation | Lot, date, concentration, storage location | Supports traceability and reproducibility |
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Peptides are short chains of amino acids that can undergo both chemical and physical degradation. Chemical pathways include hydrolysis of peptide bonds, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and isomerization of aspartate. Physical instability leads to aggregation, precipitation, or adsorption to surfaces. The rate of these processes depends on the peptide sequence, the formulation, and the storage environment. Because each peptide has a unique composition, no single storage condition applies to all peptides. Stability studies are therefore conducted to define suitable conditions for each specific molecule.
Temperature is a primary factor in peptide storage. Lower temperatures reduce molecular motion and slow degradation reactions, but freezing can concentrate solutes and promote aggregation. Lyophilized powders are commonly held at -20°C, whereas solutions are often kept at -80°C. Repeated freeze-thaw cycles are harmful because ice crystal formation and pH shifts can damage the peptide. The glass transition temperature of a lyophilized cake influences its stability; below this temperature, molecular mobility is restricted. For solutions, the choice between -20°C and -80°C depends on the peptide's sensitivity and the intended storage duration.
Moisture, oxygen, and light also affect peptide integrity. Lyophilized powders absorb water from the air, which can enable hydrolysis and conformational changes. Oxygen promotes oxidation of sensitive residues, so storage under inert gas or in sealed vials is common. Light exposure can cause photodegradation, particularly for peptides containing aromatic amino acids. Buffer choice and pH influence charge state and solubility; extremes of pH accelerate deamidation and hydrolysis. Adding stabilizers such as sugars or polyols can protect the peptide during freezing and drying. Optimal conditions are determined empirically for each peptide.
Studies in the hematopoietic system disclosed that during endothelial to hematopoietic stem cell transition, ADGRG1 is a transcriptional target of the heptad complex of hematopoietic transcription factors, and is required for hematopoietic cluster formation. Recently, two studies showed that ADGRG1, is a cell autonomous regulator of oligodendrocyte development through Gα12/13 proteins and Rho activation. Della Chiesa et al. demonstrate that ADGRG1 is expressed on CD56dull natural killer (NK) cells. Lin and Hamann's group show all human cytotoxic lymphocytes, including CD56dull NK cells and CD27–CD45RA+ effector-type CD8+ T cells, express ADGRG1.
In 1968, Carl Woese hypothesized that RNA might be catalytic and suggested that the earliest forms of life (self-replicating molecules) could have relied on RNA both to carry genetic information and to catalyze biochemical reactions—an RNA world. In May 2022, scientists discovered that RNA can form spontaneously on prebiotic basalt lava glass, presumed to have been abundant on the early Earth. In March 2015, DNA and RNA nucleobases, including uracil, cytosine and thymine, were reportedly formed in the laboratory under outer space conditions, using starter chemicals such as pyrimidine, an organic compound commonly found in meteorites. Pyrimidine, like polycyclic aromatic hydrocarbons (PAHs), is one of the most carbon-rich compounds found in the universe and may have been formed in red giants or in interstellar dust and gas clouds. In July 2022, astronomers reported massive amounts of prebiotic molecules, including possible RNA precursors, in the galactic center of the Milky Way Galaxy.
The first generation uses linking technologies that conjugate drugs non-selectively to cysteine or lysine residues in the antibody, resulting in a heterogeneous mixture. This approach leads to suboptimal safety and efficacy and complicates optimization of the biological, physical and pharmacological properties. Site-specific incorporation of unnatural amino acids generates a site for controlled and stable attachment. This enables the production of homogeneous ADCs with the antibody precisely linked to the drug and controlled ratios of antibody to drug, allowing the selection of a best-in-class ADC. An Escherichia coli-based open cell-free synthesis (OCFS) allows the synthesis of proteins containing site-specifically incorporated non-natural amino acids and has been optimized for predictable high-yield protein synthesis and folding. The absence of a cell wall allows the addition of non-natural factors to the system to manipulate transcription, translation and folding to provide precise protein expression modulation.
Several artificial nucleobases have been synthesized, and successfully incorporated in the eight-base DNA analogue named Hachimoji DNA. Dubbed S, B, P, and Z, these artificial bases are capable of bonding with each other in a predictable way (S–B and P–Z), maintain the double helix structure of DNA, and be transcribed to RNA. Their existence could be seen as an indication that there is nothing special about the four natural nucleobases that evolved on Earth. On the other hand, DNA is tightly related to RNA which does not only act as a transcript of DNA but also performs as molecular machines many tasks in cells. For this purpose it has to fold into a structure. It has been shown that to allow to create all possible structures at least four bases are required for the corresponding RNA, while a higher number is also possible but this would be against the natural principle of least effort.
Sources: en.wikipedia.org
However, β-strands are rarely perfectly extended; rather, they exhibit a twist. The energetically preferred dihedral angles near (φ, ψ) = (–135°, 135°) (broadly, the upper left region of the Ramachandran plot) diverge significantly from the fully extended conformation (φ, ψ) = (–180°, 180°). The twist is often associated with alternating fluctuations in the dihedral angles to prevent the individual β-strands in a larger sheet from splaying apart. A good example of a strongly twisted β-hairpin can be seen in the protein BPTI. The side chains point outwards from the folds of the pleats, roughly perpendicularly to the plane of the sheet; successive amino acid residues point outwards on alternating faces of the sheet.
Tranexamic acid is sometimes used in orthopedic surgery to reduce blood loss, to the extent of reducing or altogether abolishing the need for perioperative blood transfusion. It is of proven value in clearing the field of surgery and reducing blood loss when given before or after surgery. Drain and number of transfusions are reduced. In surgical corrections of craniosynostosis in children it reduces the need for blood transfusions. In spinal surgery (e.g., scoliosis), correction with posterior spinal fusion using instrumentation, to prevent excessive blood loss. In cardiac surgery, both with and without cardiopulmonary bypass (e.g., coronary artery bypass surgery), it is used to prevent excessive blood loss.
φ29’s DNA packaging system, using pRNA, incorporates a motor for the delivery of therapeutic molecules like ribozymes and aptamers. The small size of pRNA-derived nanoparticles also helps to deliver drugs in tight spaces like blood vessels. The main difficulty in using aptamer-based drug delivery is sourcing unique aptamers and other multimers for specific treatments for diseases that potentially degrade therapeutic multimers and nanoparticles in vivo. Nanoparticles need to be stabilized as delivery mechanisms in order to adapt to microenvironments that may result in loss of therapeutic cargo.
Sources: en.wikipedia.org
From 2002 to 2004, Pinhasov carried out postdoctoral research at Johnson & Johnson Pharmaceutical Research and Development (Spring House, Pennsylvania, United States), where under the guidance of Dr. Douglas Brenneman he was engaged in the development of drugs for the treatment of neurodegenerative diseases. In 2005, Pinhasov joined the Department of Molecular Biology at Ariel University (formerly the College of Judea and Samaria) as an assistant professor. He was Head of the department from 2008 to 2014. In 2014, Pinhasov was appointed Vice-President and Dean of Research & Development at Ariel University, holding this position until 2020. In 2020 the Senate of Ariel University elected Professor Pinhasov as the Rector of Ariel University, succeeding Professor Michael Zinigrad, who held this office for 12 years. In September 2023, in recognition of his contribution to academic ties between Israel and Kazakhstan, the Senate of Astana Medical University (AMU) awarded Prof. Albert Pinhasov the title of honorary professor.
Sometimes many different genes can influence a desirable trait in plant breeding. The use of tools such as molecular markers or DNA fingerprinting can map thousands of genes. This allows plant breeders to screen large populations of plants for those that possess the trait of interest. The screening is based on the presence or absence of a certain gene as determined by laboratory procedures, rather than on the visual identification of the expressed trait in the plant. The purpose of marker assisted selection, or plant genome analysis, is to identify the location and function (phenotype) of various genes within the genome. If all of the genes are identified it leads to genome sequence. All plants have varying sizes and lengths of genomes with genes that code for different proteins, but many are also the same. If a gene's location and function is identified in one plant species, a very similar gene likely can also be found in a similar location in another related species genome.
Pyocyanin (PCN−) is one of the many toxic compounds produced and secreted by the Gram negative bacterium Pseudomonas aeruginosa. Pyocyanin is a blue secondary metabolite, turning red below pH 4.9, with the ability to oxidise and reduce other molecules and therefore kill microbes competing against P. aeruginosa as well as mammalian cells of the lungs which P. aeruginosa has infected during cystic fibrosis. Since pyocyanin is a zwitterion at blood pH, it is easily able to cross the cell membrane. There are three different states in which pyocyanin can exist: oxidized (blue), monovalently reduced (colourless) or divalently reduced (red). Mitochondria play an important role in the cycling of pyocyanin between its redox states. Due to its redox-active properties, pyocyanin generates reactive oxygen species.
Sources: en.wikipedia.org
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.
Aliquoting divides a solution into smaller portions so that each portion is handled once. This reduces repeated freeze-thaw cycles and limits contamination risk. It also makes it easier to track usage and maintain consistent test conditions.
Refreezing is possible for some peptides but can promote aggregation or precipitation. The effect depends on the peptide, solvent, concentration, and freezing rate. Many laboratory protocols therefore recommend single-use aliquots instead of repeated refreezing.
Lyophilized peptides have low water activity, which slows hydrolysis and many oxidative pathways. Low temperatures further reduce residual chemical reactivity and microbial growth risk. The exact temperature depends on peptide stability data and expected storage duration.